ࡱ> O QbjbjUU 47׎e7׎eH7p p 8QyP (333$$$OOOOOOO$SUP$$$"$$P33p3P&&&$R383O&$O&&IK3@{f%v:J"OIP0yP\JV%VDKKnVTL$$&$$$$$PP%v$$$yP$$$$V$$$$$$$$$p {: INFORMED CONSENT FORM (ICF) Template Informed consent is a process that involves a comprehensive discussion between the investigator and subject in order to ensure the subject's understanding of a proposed research study. This process is documented and reinforced by a written consent form. Typically, written informed consent is required (45 CFR 46.117(a)) unless a waiver is requested and approved. Informed Consent Forms (including Parental Permission and minor Assent forms), need to be written in a manner so that they can be easily understood by the targeted readers. Each form should be modeled on the following examples and will be dated and signed at the bottom of each page by the IRB. The consent document should be written using lay language, typically at an 8th grade reading level (similar to the level used in popular magazines and newspapers) or as is appropriate for the participant population. Avoid technical jargon. The form should be written as if the investigator and participant are engaged in conversation. The form should be written in the second person (e.g., you are invited to participate, you will be asked, etc.), except for the very last item, the Statement of Consent. The use of bulleted lists, tables, and/or pictures may be helpful to explain study procedures, timelines, inclusion/exclusion criteria, etc. Font type and size should adhere to industry standards and be clear and easy to read, such as Times New Roman 12 pt. or Calibri 11 pt. In no case may the font size be reduced for the sole purpose of fitting the form onto a fewer number of pages. Page margins should be no less than 0.75. If you are doing an online survey or telephone/Zoom survey/interview, a waiver of the requirement for written informed consent may be requested. If granted, however, an informed consent process is still required, and the components of written informed consent as detailed below are still necessary. Online Surveys: The consent language must be at the beginning of the online survey (typically as item 1), and an I accept button will then provide participants access into the survey. An example of an online informed consent form is posted at the end of this document. Telephone/Zoom Surveys or Interviews: Consent language needs to be written at the beginning of the script, and verbal consent must be obtained before beginning the survey or interview. A copy of the script must be provided to the IRB. All categories below are required (45 CFR 46.116) for written informed consent unless if applicable is noted. If you have questions or need assistance, please contact the IRB office at 243-6672. PLEASE NOTE: When using the template below, do NOT include anything in brackets (in other words, delete the instructions). You must also delete this first page of instructions. We expect a final document to review. Make sure that page numbers appear properly in the upper right corner of each page. From the examples provided, select the statements that are appropriate and applicable to your study. You dont have to use all that are listed, and you may write your own text, as appropriate. In the footer of this document is the IRB stamp, which we will sign and date upon project approval. Please be sure this appears in your final document. You may also copy and paste this onto any recruitment flyers. SUBJECT INFORMATION AND INFORMED CONSENT Study Title: [Use the same title as on the corresponding IRB Application] Sponsor: [Required if the project is funded. If not funded, delete this line.] Investigator(s): [Name, department, university email and telephone number. If investigator is a student, identify and include university information for faculty supervisor.] Key Information: This section is only to be used for federally funded studies and only when the ICF is 2,000 words (about 5 pages) or longer. See guidance at the end of this template. Special Instructions: [Only use if applicable] This consent form may contain words that are new to you. If you read any words that are not clear to you, please ask the person who gave you this form to explain them to you. Inclusion Criteria: [Only use if there are specific criteria for this subject population; if not, delete this section.] In bullet format, clearly list the inclusion criteria to participate in this research. Keep the wording brief and succinct. Exclusion Criteria: [Only use if there are specific criteria for this subject population; if not, delete this section.] In bullet format, clearly list the exclusion criteria to participate in this research (do not repeat the opposite of the inclusion criteria). Keep the wording brief and succinct. Purpose: [Examples:] You are being asked to take part in a research study comparing ... You have been invited to participate because... The purpose of this research is to learn how to... The results will be used for and/or provided to You must be 18 or older to participate in this research. (may be moved up into inclusion criteria section if used) Procedures: [Examples:] If you agree to take part in this research study, you will be given ... You will be asked... A ... will be done You may also... You will be required to ... The study will take place at the ... The session will last for ... minutes. It will take about minutes to complete the survey. Payment for Participation: [If applicable; payment is NOT considered a benefit. If there is no compensation, delete this section.] [For student subjects, extra credit is considered an incentive/payment.] [Examples:] You will receive ... for each visit to help cover your travel expenses. As an incentive for participating in this study, Risks/Discomforts: [Describe the risks/discomforts, and how they will be minimized or mitigated. Typically, one cannot guarantee there are no risks/discomforts, so minimal is preferable.] [Examples:] There is no anticipated discomfort for those contributing to this study, so risk to participants is minimal. Mild discomfort may result from ... Muscle soreness may occur as a result of... Answering the questions may cause you to think about feelings that make you sad or upset. You will be informed of any new findings that may affect your decision to remain in the study. Benefits: [If there are none for the subject, say so. Payment for participation is NOT a benefit] [Examples:] There is no promise that you will receive any benefit from taking part in this study. Your participation in this study may help ... Although you may not directly benefit from taking part in this study, ... Alternative Therapy: [Disclose if applicable] [Example:] If you choose not to take part in this study, other treatments can be used/may be available. These would include... Confidentiality: [Confidentiality means the researcher will maintain records with personal identifiers but will not release information to unauthorized personnel. Anonymity means that records will not include any personal identifiers or code numbers that may link a participant to specific information.] [Required:] Your records will be kept confidential and will not be released without your consent except as required by law. [Examples:] Your identity will be kept private. If the results of this study are written in a scientific journal or presented at a scientific meeting, your name will not be used. Your initials _________ indicate your permission to be identified by name in any publications or presentations. If you do not want to be acknowledged by name in any publications or presentations, please initial here _________. The data will be stored in a locked file cabinet. Your signed consent form will be stored in a cabinet separate from the data. The audiotape will be transcribed without any information that could identify you. The tape will then be erased [or destroyed]. Voluntary Participation/Withdrawal: [Examples:] Your decision to take part in this research study is entirely voluntary. You may refuse to take part in or you may withdraw from the study at any time without penalty or loss of benefits to which you are normally entitled. If you decide to withdraw, ... You may leave the study for any reason. You may be asked to leave the study for any of the following reasons: 1. Failure to follow the Project Directors instructions; 2. A serious adverse reaction which may require evaluation; 3. The Project Director thinks it is in the best interest of your health and welfare; or 4. The study is terminated. Future research: [Required. For any research that involves the collection of identifiable private information or identifiable biospecimens, the ICF must now include a notice about whether information and/or biospecimens collected as part of the current research might be stripped of identifiers and used for future research. Include one of the following statements as appropriate (adjust wording):] Identifiers might be removed from the identifiable private information [or identifiable biospecimens] and could then be used for future research studies or distributed to another investigator for future research studies without additional informed consent from you or your legally authorized representative. OR Your information [or biospecimens] collected as part of the research, even if identifiers are removed, will not be used or distributed for future research studies. [We suggest using caution when implementing the second statement in your ICF, as it can be very challenging to keep subjects information or biospecimens from being used for future research. This is not to say the second statement should not be used; researchers will just need to be extra vigilant to make sure the information/biospecimens are used or not used in accordance with the ICF.] Commercial profit: [Include only when appropriate] A statement that the subjects biospecimens (even if identifiers are removed) may be used for commercial profit and whether the subjects will or will not share in this profit. Clinically relevant results: [Include only when appropriate] A statement whether clinically relevant research results, including individual research results, will be disclosed to subject and, if so, under what conditions. Genome sequencing: [Include only when appropriate] For research involving biospecimens, whether the research will (if known) or might include whole-genome sequencing (i.e., sequencing of a human germline or somatic specimen with the intent to generate the genome or exome sequence of that specimen). Questions: [Optional:] You may wish to discuss this with others before you agree to take part in this study. [Required:] If you have any questions about the research now or during the study, please contact: [Study director name and telephone number]. If you have any questions regarding your rights as a research subject, you may contact the UM Institutional Review Board (IRB) at (406) 243-6672. Statement of Your Consent: [Required:] I have read the above description of this research study. I have been informed of the risks and benefits involved, and all my questions have been answered to my satisfaction. Furthermore, I have been assured that any future questions I may have will also be answered by a member of the research team. I voluntarily agree to take part in this study. I understand I will receive a copy of this consent form. Printed Name of Subject ________________________ Subject's Signature Date Statement of Consent to be Photographed [and/or Audiotaped, Videotaped, etc., if applicable]: [Examples:] I understand that photographs (audio/video recordings) may be taken during the study. I consent to having my photograph taken. (being audio/video recorded) I consent to use of my photograph (audio/video) in presentations related to this study. I understand that if photographs (audio/video recordings) are used for presentations of any kind, names or other identifying information will not be associated with them. I understand that audio recordings will be destroyed following transcription, and that no identifying information will be included in the transcription. ________________________ Subject's Signature Date [Alternatively, consent for photographing (audio recording, video recording, etc.), can be indicated within the document under the Procedures section by including a place for the subject to initial and be informed as follows:] * Your initials _________ indicate your permission to audio (video) record (photograph) the interview. * Your photograph (audio/video) may be used in presentations related to this study. *If your photograph (audio/video recordings) is used for presentations of any kind, names or other identifying information will not be associated with it. * Audio recordings will be destroyed following transcription, and no identifying information will be included in the transcription. ____________________________________________________________________________________ Compensation for Injury: [If appropriate: This clause is typically required for research involving more than minimal risk. Generally speaking, this will apply to most projects requiring full IRB committee review; however, the IRB may require it for some expedited projects that involve physical measurements, testing, or interventions. If in doubt, consult with the IRB office. Insert this clause above the Questions section above.] In the event that you are injured as a result of this research you should individually seek appropriate medical treatment. If the injury is caused by the negligence of the ؿ or any of its employees, you may be entitled to reimbursement or compensation pursuant to the Comprehensive State Insurance Plan established by the Department of Administration under the authority of M.C.A., Title 2, Chapter 9. In the event of a claim for such injury, further information may be obtained from the Universitys Risk Manager (406-243-2700; HYPERLINK "mailto:jason.sloat@mso.umt.edu"jason.sloat@mso.umt.edu) or the Office of Legal Counsel (406-243-4742;  HYPERLINK "mailto:legalcounsel@umontana.edu" legalcounsel@umontana.edu). (Reviewed by University Legal Counsel, December 31, 2018) ____________________________________________________________________________________ EXAMPLE ONLINE SURVEY CONSENT FORM [Note: For online surveys, you must also submit the  HYPERLINK "http://www.umt.edu/research/compliance/IRB/Docs/Online%20Survey%20Confidentiality.doc" Statement of Confidentiality form.] You are invited to participate in a research project about [subject or project title]. This online survey should take about [x to x] minutes to complete. Participation is voluntary, and responses will be kept anonymous [if you never know the subjects identity] [or confidential if you do know the subjects identity] to the degree permitted by the technology being used. You have the option to not respond to any questions that you choose. Participation or nonparticipation will not impact your relationship with the ؿ. Submission of the survey will be interpreted as your informed consent to participate and that you affirm that you are at least 18 years of age. If you have any questions about the research, please contact the Principal Investigator, [name], via email at  HYPERLINK mailto:bertha.deblues@mnsu.edu [email address] or the faculty advisor [if applicable], Dr. [name] at  HYPERLINK mailto:seymour.kleerly@mnsu.edu [email address]. If you have any questions regarding your rights as a research subject, contact the UM Institutional Review Board (IRB) at (406) 243-6672. Please print or save a copy of this page for your records. * I have read the above information and agree to participate in this research project. ____ Enter survey ______________________________________________________________________________ Key Information: This section is only to be used for federally funded studies and only when the ICF is 2,000 words (about 5 or 6 pages) or longer. You can see the total word count in Word in the status bar in the lower left corner of your screen. Key information about the study must be provided at the beginning of the ICF. The presentation must be concise and focused, and the information should be provided in sufficient detail, organized and presented in a way that helps subjects think about why they might or might not want to participate. The standard is to provide the information that a reasonable person would want to have in order to make an informed decision about whether to participate. Consider the following questions when writing your key information: What are the main reasons a subject will want to join this study? What are the main reasons a subject will not want to join this study? What is the research question the study is trying to answer? Why is it relevant to the subject? What aspects of research participation in this particular study are likely to be unfamiliar to a prospective subject, diverge from a subjects expectations, or require special attention? What information about the subject is being collected as part of this research? What are the types of activities that subjects will do in the research? What impact will participation in this research have on the subject outside of the research? For example, will it reduce options for standard treatments? How will the subjects experience in this study differ from treatment outside of the study? In what ways is this research novel? Note that if information included in the key information section also satisfies the basic elements or additional elements of informed consent (under  HYPERLINK "https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=83cd09e1c0f5c6937cd9d7513160fc3f&pitd=20180719&n=pt45.1.46&r=PART&ty=HTML" \l "se45.1.46_1116" 45 CFR 46.116[b] and [c]), this information does not need to be repeated later in the ICF. For NIH-funded clinical trials, you must include the following statement: A description of this clinical trial will be available on  HYPERLINK "http://www.ClinicalTrials.gov" http://www.ClinicalTrials.gov, as required by U.S. law. This website will not include information that can identify you. At most, the website will include a summary of the results. You can search this website at any time.     Page  PAGE 2 of  NUMPAGES 2  The ؿ IRB Expiration Date_________________________ Date Approved _________________________ Chair/Admin ___________________________ $%&C# $ % Z  E f   E H ϵxlcUh>Ph>P6mHnHuheY'mHnHuh>PheY'mHnHuh>PmHnHuh(mHnHuh>Ph>PH*mHnHuh>Ph>PmHnHuh6-mHnHuh"hh> hphth( hKhKhKhPq hPqhPqhPqhPq5\ht htht h.5\htht5\!%&$ %  K no & F E1$7$8$H$^`Egd6- /8p@ P !$gd"! /8p@ P !$`gdt $ /8p@ P !$a$gd. H e h i } J K AmnorzѶxssogochKhKhOw>*hOw hH~5 hH~hH~ hy5h>Ph"5hPqh"hMFh>Ph;omHnHuh&,)mHnHuhY4mHnHuh;omHnHuh6-mHnHuheY'mHnHuh>PmHnHuh>Ph>P6mHnHuheY'6mHnHuh>Ph>PmHnHu& CDMt~-45=OYfi abcjqrhkB*phhx 'hB*phhB*phhV?mB*phhh.zhdMhyh=q5hNhyhE3hyhy>*hyhH~>*hH~hMFh"hKhOw:obcrU||XX$$ & F ,p@ P !$1$a$gdV?m $ ,p@ P !$1$a$gd /8p@ P !$gdOw' & F ,p@ P !$L^`LgdH~ ,p@ P !$gdH~ =TU+,-MUVWX^_cfjǿzslgb]XbQJ hpht hht hv\ h G\ h\ h[o\ huS65\ h5\ hEC5\ hdM5\hdMhpht>*hpht5\ h4'5\ h5\h`PqhtB*phh`PqB*phh*B*phh>B*phhB*phhbmB*phhkB*phhV?mB*phh2kB*phh= B*phU,VWXxZ ,p@ P !$1$gd$p$($ ,p@ P !$@ 1$^@ `a$gdt $ ,p@ P !$1$a$gdt$  HP !$1$a$gd>$$ & F ,p@ P !$1$a$gd U  &@FSuw_`iuwx@ƿ㣸㜣뎊{wshhVth_ h`'5\h0h G h G5\ hh hhS hhcb hh$p$ hht hh7_E h U5\hpht5\ h5\hthzVhhehOw hpht huS65\ h5\*_`w}W% ,p@ P !$p`1$^p``gdJ-D@M [$\$^gd G)$ ,p@ P !$-D@1$M a$gdJ $ ,p@ P !$1$a$gdt ) p@ P !$1$^gd7_E@AU56JppJ% ,p@ P !$`1$^``gdzV% & F ,p@ P !$1$^gdX-! ,p@ P !$1$^gd% ,p@ P !$`1$^``gdJ! ,p@ P !$1$^gd @AJU456J`abjkluvwP KL")O»»»|hzUhX-hm \h!shhP0h U hphrho^h+hVththQhh_ hphthpht5\hhzV\ hzV\hhX-\ hX-\ h\ h5\ hzV5\ hr5\0J<abkwlJJ! ,p@ P !$1$^gd % ,p@ P !$p`1$^p``gdJ% ,p@ P !$`1$^``gdJ% & F ,p@ P !$1$^gdzV! ,p@ P !$1$^gdzVP$9M]{w% ,p@ P !$p`1$^p``gdJ ,p@ P !$1$gdJ! ,p@ P !$p1$`pgdJ! ,p@ P !$1$^gd {!TU[[$ ,p@ P !$p`^p``gdJ ,p@ P !$^gdX-$ ,p@ P !$@ ^@ `gdJ ,p@ P !$gdJ ,p@ P !$^gd  !TUZ[ghi{|  # !ƾƾwowkhh7_Ehm \6h7_Eht6hr h5\hvu=h+h8{h56h8{h6h8{ht56h8{hm \6h8{h06h8{ht6h8{hX76 hrhr h05\hpht5\ hphrhth;3h_ hpht'Uh 9 yyVyy#$ ,`0p@ P ^a$gd ,p@ P !$^gd '$ ,p@ P !$p`^p``a$gdt ,p@ P !$^gdX7$ ,p@ P !$a$gdr !^!!!!!"o'$ ,p@ P !$@ ^@ `a$gdt$ ,p@ P !$a$gdt#$ ,p@ P !$^a$gd '$ ,p@ P !$`^``a$gdt !]!^!c!x!!!!!!!!!!!!!"""Z"k"""""#########$$$ $3$?$Z$a$$$X%%%%м hphvhvhQ$h hvu=hlj *hpXh = *hpXh8{ h6hh6 h.46h8{h_h U6h_hr6h_ht6hrhpht5\h6IhzU hphth hph0"""""##3$?$c$$X%%%J&&&&$ ,p@ P !$a$gdt'$ ,p@ P !$p`^p``a$gdt ,p@ P !$^gd %%&&&&&&G'H'''j(((e)f)w)x)))))1*4*********<+=+Y+Z++,),+,,,0,=,>,M,N,,,,,..0.U.V.W.X.ŻųųųųųųųųųhI:hI:>*hI:hI:5\h2k hI:hI:hI:hI:hI:6 *h!DhI:6h!DhI:6 hI:5\ h: 0Jhpht0Jhfhpht5\hpX hphthd8&&G'''$(j(((E)e)f)w)*),,,1$7$8$H$^gdI: 1$7$8$H$gdI: ,p@ P !$gdvu=! ,p@ P !$1$^gd ,p@ P !$^gd ,,,W.X.k.=/>/\/0 030N1O1Z1$ ,p@ P !$a$gdt$ ,p@ P !$a$gdge1$7$8$H$^gdge 1$7$8$H$gdge1$7$8$H$^gdI: X.i.k../Y/Z/[/\/{/00 01030R0N1O1Y1Z1c1d1e1f1g1111111222-2I2J2K2222222222222223ļĴĨļļĕˎĴ hO5\ ht5\hsnhhP ht *hl~hO *hl~h`'hOh`' hphthpht5\ hgehI:hge hgehgehgehge\ hge5\hgehge5\6Z1g111L22223444||$ ,p@ P !$p`^p``gdd ,p@ P !$^gdH$ ,p@ P !$a$gdt ,p@ P !$^gd 333v334444444445R5T5l555555555555555555566 6(6񸮧uqjqfh hphh`'h<>h5\ h\ h \ hdM\ h`'\ hA \hh\ h<>5\ h U5\hph5\ hph Uhth.zhtCJaJh.zhsnCJaJhpht>*hphd>*hdht hphthOh:'445 555555 6c6677rrrrr ,p@ P !$^gdH$ ,p@ P !$a$gd'$ ,p@ P !$P^`Pa$gdt'$ ,p@ P !$P^`Pa$gdA (6A66666666667#7<7C7c7777E8F8N8O8888888888899:9;9b9m9u9v999999999::G:I:N:g:s::::::::1;4;6;7;쿻췳컷쨿쨿 hphxvhrwh`'hKhA h]h.zhCJaJ hphhph>*hph U>* hxvhxvhxvh0hdMhh UB7G8N8O8888\'$ ,p@ P !$P^`Pa$gd'$ ,p@ P !$P^`Pa$gdA $ ,p@ P !$p`^p``gd pp^pgdxv ,p@ P !$^gdH889G::6;;;;<yZZ$ ,p@ P !$a$gdN ,p@ P !$p^pgdxv ,p@ P !$^gdH" ) p@ P !$0^`0gd]" ) p@ P !$0^`0gdxv 7;8;>;;;;;<<<*<+<,<L<^<`<v<<<<<<<#=a=====~>>_?`?o????@ƿƵƵ͊͊͂zmzjhKB*UphhKB*phhSBB*phhSB(hhhSB0JB*OJQJ]^Jph hd#=6]h7_EhSB56]h7_EhSB6] h2k6] hSB6] hphSBhphSB5\ hSB5\h.RhhN hxvhxvh]hxv%<<,<=@@BACAfA|`W $1$a$gd.R ,p@ P !$gdN$ ,p@ P !$a$gdN # p@ P ^gdSB^gdK ,p@ P !$^gd&1$ ,p@ P !$a$gdSB@@@2@3@5@c@d@@@@@@@@@@@AABACAKALAMAͮ͛}gS&hR KhN5CJOJQJ\^JaJ*hR KhN5@CJOJQJ\^JaJ*hR Kh.R5@CJOJQJ\^JaJhNhSB hphSBh)eB*CJaJphhSBB*CJaJph hSB0JjhSBB*UphhSBB*phhB*ph hK0JjhKB*UphjhKB*UphMAOAQARASATAUAVAWAXAYAZA\A]A^A`AaAbAeAfA֔~֪hRA hR KhNCJOJQJ^JaJ*hR KhN5@CJOJQJ\^JaJ*hR KhN5@CJOJQJ\^JaJ*hR KhN5@CJOJQJ\^JaJ*hR KhN5@CJOJQJ\^JaJ*hR KhN5@CJOJQJ\^JaJ*hR KhN5@CJOJQJ\^JaJ&hR KhN5CJOJQJ\^JaJ*hR KhN5@CJOJQJ\^JaJfAAAABBBB%B&B'B(B)B*B+BӔn]J]7$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ hN>hvMCJOJQJ^JaJ hN>hR KCJOJQJ^JaJ)hR KhNB*CJOJQJ^JaJph$hR KhR K0JCJOJQJ^JaJ2jhR KB*CJOJQJU^JaJph#hR KB*CJOJQJ^JaJph,jhR KB*CJOJQJU^JaJph)hR KhR KB*CJOJQJ^JaJphfA&B'BCCDDFFFFGG0GGG ,p@ P !$gdN$dl1$]^d`la$gdnOdl1$]^d`lgdnOd1$]^dgdN1$gd&1 d 1$gdN$d 1$a$gdR K+B,B-B.B/B6B7B9B:B;BB?B@BABBBڶɐ}jWD1$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>h@CJOJQJ^JaJ hN>hvMCJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJBBCBDBEBFBGBHBIBKBLBMBNBPBQBRBSB[Bɶɐ}jWjD3 hN>hCJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>h@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ hN>hvMCJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ[B\BaB|B~BBBBBBBBBBBBBBBBǶlYF3F$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ hN>hICJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@ CJOJQJ^JaJ hN>hvMCJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>h@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJBBBBBBBBBBBBBBBBBBBBBBBBBBBɶ}jWɶ}D$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ hN>hvMCJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJBBBBBBBBBBBBBBBBBBBBBBBBBǴڡ}jWڴڐDǐ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ hN>hvMCJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJBBBBBBBBBBBBBBBBBBBǴ}j}WD1}$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ hN>hvMCJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@ CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJBBBBBBBBBBBBBBBBBBBBBBBɶܣܐ}jWܶDjj$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ hN>hvMCJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJBCCfCCCCCCCCCCCCCCCCCCCCCǴ}jWjDjDjڣ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ hN>hvMCJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJCCCCCCCCCCCCCCCCCCCɶܣ}jWDܣ}$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ hN>hvMCJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJCCCCCCCCCCCCCCCCCCCɶܣ}jWD1j$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ hN>hvMCJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJCCCCCCCCCCCCCCCCǴ}jWD1$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@ CJOJQJ^JaJ hN>hvMCJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJCCCCCCCCCCCCCCCCCCDDDDDDDDDǶǶǐ}jWD}ǶWD$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ hN>hvMCJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@ CJOJQJ^JaJD D D D DDDDDDDDDDDDDDDɶ}jWD}1$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ hN>hvMCJOJQJ^JaJDD D!D"D#D$D%D&D'D(D)D*D+D,D-D.DFDHDǴǣ}jǴWG4$hN>hvM@CJOJQJ^JaJhH@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@ CJOJQJ^JaJ hN>hvMCJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@ CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJHDIDLDMDNDODPDQDRDSDTDUDVDWDXDYDZD[D\Dɶ}j}WD1ܣ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@ CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ hN>hvMCJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ\D]D^D_D`DaDbDcDdDeDfDhDiDjDkDlDmDnDoDǶǶ}jWD$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ hN>hvMCJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJoDpDqDrDsDtDuDvDxDyDzD|D}D~DDDDDDڶڶǶ}jWD1$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ hN>hvMCJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJDDDDDDDDDDDDDDDDDDDDDDDDDDDɐ}}jWD$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ hN>hvMCJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJDDDDDDDDDDDDDDDDDDɶ}ܣjWD1$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ hN>hvMCJOJQJ^JaJDDDDDDDDDDDDDDDDDDDǴ}ڣjWWD1$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ hN>hvMCJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJDDDDDDDDDDDDDDDDDDDDǶ}jWF3$hN>hN@CJOJQJ^JaJ hN>hNCJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ hN>hvMCJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJ$hN>hvM@CJOJQJ^JaJDDDDDDDDDDDDDDDDDDɶ}jWD1$hN>hN@ CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ hN>hNCJOJQJ^JaJDDDDDDDDDDDDDDEEEEEEEE E E E E Eɶɐڣ}j}WWD$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ hN>hNCJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ EEEEEEEEEE2E3E7E8E9E:E;EǴǡ}jWD1D1}$hN>h@CJOJQJ^JaJ$hN>hnO@CJOJQJ^JaJ$hN>h@ CJOJQJ^JaJ$hN>hN@ CJOJQJ^JaJ hN>䴳ϴ$N>Cϴ$N>Cϴ$N>Cϴ$N>䴳ϴ$N>䴳ϴ$N>䴳ϴ;E?E@EAECEDEEEGEHErEsEtEzE{EEɶܣ{c{P{? hN>hnOCJOJQJ^JaJ$hN>hnO@CJOJQJ^JaJ/jhN>hNCJOJQJU^JaJ)jhN>hNCJOJQJU^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ hN>hNCJOJQJ^JaJ$hN>hN@CJOJQJ^JaJEEEEEEEEEEEEEEEɸp]F3$hN>hN@CJOJQJ^JaJ-jhN>hN@CJOJQJU^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ hN>hICJOJQJ^JaJ hN>hnOCJOJQJ^JaJ hN>hCJOJQJ^JaJ hN>hNCJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJEEEEEEEEEEFFFFFλ΄q^K8%$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ hN>hNCJOJQJ^JaJ$hN>hnO@CJOJQJ^JaJ-jhN>hN@CJOJQJU^JaJ3jhN>hN@CJOJQJU^JaJFFFFFAFBFCFDFEFFFGFHFIFJFKFLFMFNFOFɶlYF$hN>hN@CJOJQJ^JaJ$hN>hN@ CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ hN>hnOCJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ hN>hNCJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJOFRFrFsFtFuFvF{F|FFFFFFFFǴlYYF3$hN>h6 @CJOJQJ^JaJ$hN>hj@CJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ$hN>hnO@CJOJQJ^JaJ hN>hnOCJOJQJ^JaJ$hN>hN@CJOJQJ^JaJ hN>䴳ϴ$N>Cϴ$N>䴳ϴ$N>󳮰䴳ϴ$N>䴳ϴFFFF0ʳGGGɱHH豷籷'(OOOOOOhnO6@CJOJQJ^JaJ$hN>hnO@CJOJQJ^JaJ$hN>h6 @CJOJQJ^JaJ hN>h6 CJOJQJ^JaJ$GGxHyHI?J@JJJ KlK'LwLLYM & F-D@1$7$8$H$M gdJ & F-D@1$7$8$H$M gdJ-D@1$7$8$H$M gdJ-D@M [$\$gdJ-D@M [$\$gdJ-D@1$7$8$@&H$M gdJYMMMMkOlOmOOPQQQQQQ Q Q-Q.Q$a$ ,p@ P !$gd G-D@1$7$8$H$M gdJ-D@M [$\$gdJ & F-D@1$7$8$H$M gdJAP`PPPPPPPPQQQQQQ QQQQQQQQQ)Q*Q+Q,Q.Q/Q0Q3Q4Q5QSQdQoQuQ|QQQQQQQQQQQQ鹵靏~~~~~~~ hhh>CJOJQJ^JaJh>CJOJQJ^JaJ'hrRh>5@CJOJQJ^JaJh`L6h>jh>UmHnHuh2k5\mHnHu h2k5\jh2k5U\h2khDjhDU hHUhHUhHU1.Q/Q1Q2Q3Q4Q5QSQ|QQQQQQ ,p@ P !$gd GP<gd><gd>$a$gd>gd> QQQQQQQhHUhDh>#hhh>5CJOJQJ^JaJh>CJOJQJ^JaJ hhh>CJOJQJ^JaJ21h:p>/ =!8"8#8$% DyK yK Vmailto:jason.sloat@mso.umt.eduyX;H,]ą'c-DyK yK http://www.umt.edu/research/compliance/IRB/Docs/Online Survey Confidentiality.docyX;H,]ą'cDyK yK Vmailto:bertha.deblues@mnsu.eduyX;H,]ą'cDyK yK Xmailto:seymour.kleerly@mnsu.eduyX;H,]ą'cDyK yK Vhttp://www.clinicaltrials.gov/yX;H,]ą'cw00h02 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@ 0@6666_HmH nH sH tH L`L tNormal1$7$8$H$CJ_HaJmH sH tH R@BR  G Heading 4dd1$7$8$@&H$[$\$5\DA D Default Paragraph FontRiR  Table Normal4 l4a (k (No List NoN t QuickFormat1B*CJOJQJ^JaJph&o& tLevel 46U`6 " Hyperlink >*B*ph4@"4 >0Header  H$6/16 >0 Header CharCJaJ4 @B4 >0Footer  H$6/Q6 >0 Footer CharCJaJHbH > Balloon TextCJOJQJ^JaJN/qN >Balloon Text CharCJOJQJ^JaJ*W`* ge`Strong5\N^@N I:0 Normal (Web)dd1$7$8$H$[$\$B/B  GHeading 4 Char5CJ\aJPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭VGRU1a$N% ʣꂣKЛjVkUDRKQj/dR*SxMPsʧJ5$4vq^WCʽ D{>̳`3REB=꽻Ut Qy@֐\.X7<:+& 0h @>nƭBVqu ѡ{5kP?O&Cנ Aw0kPo۵(h[5($=CVs]mY2zw`nKDC]j%KXK 'P@$I=Y%C%gx'$!V(ekڤք'Qt!x7xbJ7 o߼W_y|nʒ;Fido/_1z/L?>o_;9:33`=—S,FĔ觑@)R8elmEv|!ո/,Ә%qh|'1:`ij.̳u'k CZ^WcK0'E8S߱sˮdΙ`K}A"NșM1I/AeހQתGF@A~eh-QR9C 5 ~d"9 0exp<^!͸~J7䒜t L䈝c\)Ic8E&]Sf~@Aw?'r3Ȱ&2@7k}̬naWJ}N1XGVh`L%Z`=`VKb*X=z%"sI<&n| .qc:?7/N<Z*`]u-]e|aѸ¾|mH{m3CԚ .ÕnAr)[;-ݑ$$`:Ʊ>NVl%kv:Ns _OuCX=mO4m's߸d|0n;pt2e}:zOrgI( 'B='8\L`"Ǚ 4F+8JI$rՑVLvVxNN";fVYx-,JfV<+k>hP!aLfh:HHX WQXt,:JU{,Z BpB)sֻڙӇiE4(=U\.O. +x"aMB[F7x"ytѫиK-zz>F>75eo5C9Z%c7ܼ%6M2ˊ 9B" N "1(IzZ~>Yr]H+9pd\4n(Kg\V$=]B,lוDA=eX)Ly5ot e㈮bW3gp : j$/g*QjZTa!e9#i5*j5ö fE`514g{7vnO(^ ,j~V9;kvv"adV݊oTAn7jah+y^@ARhW.GMuO "/e5[s󿬅`Z'WfPt~f}kA'0z|>ܙ|Uw{@՘tAm'`4T֠2j ۣhvWwA9 ZNU+Awvhv36V`^PK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!g theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] II 116669H @!%X.3(67;@MAfA+BBB[BBBBBBCCCCDDHD\DoDDDDDDD E;EEEFOFFAPQQ)+,.037:<?ACFHIJLMNOPQRSTUVWXYZ[\]^_`abcdefghilnoUJ{U "&,,Z1478<fAGYM.QQ*-/1245689;=>78288889::======'GØ4 p;fɑ3׶Vc.ӵn(&poPK!8! _rels/.relsj0 }qN/k؊c[F232zQLZ%R6zPT]( LJ[ۑ̱j,Z˫fLV:*f"N.]m@= 7LuP[i?T;GI4Ew=}3b9`5YCƵkρؖ9#ۄo~e?zrPK! +drs/e2oDoc.xmlSn0 }81ri8EÀFcaIJGilo P"utxHoQ|6r&F}Ϳ?ݿ,D h27Uu#=#ռUED' :i٢7E'tr:]=y2|VmLלż^lP=N OPw (1`'Mm9P6Ū.=K@ 5*Ah |bMy}U ⹊ V8RCHtd9ҌE,=NaQc,tRa:>}Vۛa ";P2SOd ;K˚Cl ,PK-!8[Content_Types].xmlPK-!8! /_rels/.relsPK-! +.drs/e2oDoc.xmlPK-!EΏwdrs/downrev.xmlPK} 0(  B S  ?19'tHIIIIII I I4I5IIIc g 88HIIIIII I I4I5III333] f HI] f HHIIIIIII I I4I5I5IIIIO>8h9pl(-p(p(?s[8x DD^DAm6J<!V) ?Vĺ( X( i`O`UvV̸~`z·8^8`OJPJQJ^J) ^`hH.  L^ `LhH.  ^ `hH. x^x`hH. HL^H`LhH. ^`hH. ^`hH. L^`LhH.h^`OJQJo(hHhp^p`OJQJ^Jo(hHoh@ ^@ `OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHh^`OJQJo(hHhP^P`OJQJ^Jo(hHoh ^ `OJ QJ o(hH ^ `OJPJQJ^Jo( ^ `OJQJ^Jo(hHox^x`OJ QJ o(hHH^H`OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHoX ^X `OJ QJ o(hH ^ `OJPJQJ^Jo( ^ `OJQJ^Jo(hHox^x`OJ QJ o(hHH^H`OJQJo(hH^`OJQJ^Jo(hHo^`OJ QJ o(hH^`OJQJo(hH^`OJQJ^Jo(hHoX ^X `OJ QJ o(hHh^`OJQJo(hHhp^p`OJQJ^Jo(hHoh@ ^@ `OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHh^`OJQJo(hHhP^P`OJQJ^Jo(hHoh ^ `OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohp^p`OJ QJ o(hHh@ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohP^P`OJ QJ o(hH^`CJOJQJo(^`CJOJQJo(opp^p`CJOJ QJ o(@ @ ^@ `CJOJ QJ o(^`CJOJ QJ o(^`CJOJ QJ o(^`CJOJ QJ o(^`CJOJ QJ o(PP^P`CJOJ QJ o(h ^`OJQJo(h ^`OJQJo(oh pp^p`OJ QJ o(h @ @ ^@ `OJQJo(h ^`OJQJo(oh ^`OJ QJ o(h ^`OJQJo(h ^`OJQJo(oh PP^P`OJ QJ o(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJ QJ o(@ @ ^@ `CJOJ QJ o(^`CJOJ QJ o(^`CJOJ QJ o(^`CJOJ QJ o(^`CJOJ QJ o(PP^P`CJOJ QJ o(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJ QJ o(@ @ ^@ `CJOJ QJ o(^`CJOJ QJ o(^`CJOJ QJ o(^`CJOJ QJ o(^`CJOJ QJ o(PP^P`CJOJ QJ o(^`CJOJQJo(^`CJOJQJo(opp^p`CJOJ QJ o(@ @ ^@ `CJOJ QJ o(^`CJOJ QJ o(^`CJOJ QJ o(^`CJOJ QJ o(^`CJOJ QJ o(PP^P`CJOJ QJ o(h^`OJQJo(hHh^`OJQJ^Jo(hHohp^p`OJ QJ o(hHh@ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJ QJ o(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohP^P`OJ QJ o(hH^`o() ^`hH. pL^p`LhH. @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PL^P`LhH.^`o() ^`hH. pL^p`LhH. @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PL^P`LhH.-p(?~`zUvO6J i` D[8!V?V X9p^D                 6        fD                                                              Q8PVE+nT!uG'yR>vMSvMFa I: % ef A M P x[\(_P`.zyAOI6k>ISB[p_8{pX?fX7i"$p$`'x '('eY'&,)&+#-6-X-Y./P0;3E3`L6uS688Y; =d#=vu=N>^FAECazC7_EG G%JR K K/KM_SMdMnO>PSQ.RS UHUzU*VzVLW!XNqZm \ ]o^cbge fh[iP'j^jlj{k2kbmV?m;o[o[pPq=q.q`Pqmrrsr!s@MstVt}\v0wOwzxxz~&1Qxv+|K(MtyR6 J)\h<>AOzD$nNEe vDj 6I-<H~,Y4:fk)eHK0:"%*J%Xl~.4!D BvLrwy-I:dq Gz.Q$0]ksn= K4'f(d0[h64yHI@;;;;I@Unknown G.[x Times New Roman5Symbol3. .[x Arial7..{$ CalibriA. Arial Narrow5Shruti5. .[`)TahomaC.,.{$ Calibri Light?= .Cx Courier New;WingdingsA$BCambria Math"hgJzgj3G& >% >%!8824HH 3qHP ?t2! xx+ .EXAMPLES OF WORDING FOR INFORMED CONSENT FORMSjudy.fredenberg Baker, PaulaD         Oh+'0 (4 T ` l x0EXAMPLES OF WORDING FOR INFORMED CONSENT FORMSjudy.fredenbergNormalBaker, Paula7Microsoft Office Word@dN@6=U@“~@:f > ՜.+,D՜.+,t0 hp  The ؿ%H /EXAMPLES OF WORDING FOR INFORMED CONSENT FORMS Title 8@ _PID_HLINKSAl*,6http://www.clinicaltrials.gov/]j|https://www.ecfr.gov/cgi-bin/retrieveECFR?gp=&SID=83cd09e1c0f5c6937cd9d7513160fc3f&pitd=20180719&n=pt45.1.46&r=PART&ty=HTMLse45.1.46_1116B$  mailto:seymour.kleerly@mnsu.edun mailto:bertha.deblues@mnsu.edu]Rhttp://www.umt.edu/research/compliance/IRB/Docs/Online Survey Confidentiality.doc 2!mailto:legalcounsel@umontana.edu]nmailto:jason.sloat@mso.umt.edu  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnoqrstuvwyz{|}~Root Entry F|fData p1TablexVWordDocument4SummaryInformation(DocumentSummaryInformation8CompObjr  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q